0000899243-21-010463.txt : 20210308
0000899243-21-010463.hdr.sgml : 20210308
20210308200123
ACCESSION NUMBER: 0000899243-21-010463
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210308
FILED AS OF DATE: 20210308
DATE AS OF CHANGE: 20210308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Jacobs Bruce N.
CENTRAL INDEX KEY: 0001821074
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39460
FILM NUMBER: 21723684
MAIL ADDRESS:
STREET 1: C/O KYMERA THERAPEUTICS, INC.
STREET 2: 200 ARSENAL YARDS, SUITE 230
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kymera Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815442
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 812992166
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 TECHNOLOGY SQUARE
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 857-285-5314
MAIL ADDRESS:
STREET 1: 300 TECHNOLOGY SQUARE
STREET 2: 2ND FLOOR
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-03-08
0
0001815442
Kymera Therapeutics, Inc.
KYMR
0001821074
Jacobs Bruce N.
C/O KYMERA THERAPEUTICS, INC.
200 ARSENAL YARDS BLVD., SUITE 230
WATERTOWN
MA
02472
0
1
0
0
Chief Financial Officer
Common Stock
2021-03-08
4
M
0
10000
2.08
A
10000
D
Common Stock
2021-03-08
4
S
0
7699
50.4587
D
2301
D
Common Stock
2021-03-08
4
S
0
2300
51.2767
D
1
D
Common Stock
2021-03-08
4
S
0
1
52.15
D
0
D
Stock Option (Right to Buy)
2.08
2021-03-08
4
M
0
10000
0.00
D
2030-08-19
Common Stock
10000
244061
D
This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on November 6, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $50.00 to $50.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $51.00 to $51.57. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.
/s/ Bruce N. Jacobs
2021-03-08